A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Older Adults

StatusNot Yet Recruiting
PhasePhase 3
SponsorPfizer
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Pfizer
441 trials monitored
See 30 trials at risk
This study is testing the safety and tolerability of a second dose of Respiratory Syncytial Virus Vaccine (RSVpreF) given approximately 5 years after the initial dose.
Trial Details
NCT Number NCT07885956
Lead Sponsor Pfizer
Conditions
(from sponsor)		 Respiratory Syncytial Virus (RSV)
Enrollment 750 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov